June 1, 2021
Standard Bariatrics Secures $35M in Series B Funding to Accelerate Development and Commercialization of Their First Bariatric Surgical Platform for Sleeve Gastrectomy
CINCINNATI, June 1, 2021 /PRNewswire/ -- Cincinnati-based Standard Bariatrics, Inc., has developed the Titan SGS™, a first-of-its-kind design that offers surgeons performing sleeve gastrectomy, the top bariatric surgical procedure for obesity disease, the…
May 5, 2021
Business North Carolina’s Power List 2021
Congratulations to our esteemed Hatteras Venture Partners colleague Bob Ingram on his recognition for the Business NC Power List for Finance and Insurance 2021. https://businessnc.com/power-list-2021/finance-insurance/
April 28, 2021
CROs dMed and Clinipace Merge to Accelerate Customer Success
The combined Company will provide full-service CRO services to meet needs of global fast-moving biotech, pharma and medical device companies, and to accelerate the delivery of innovative solutions to patients…
March 2, 2021
Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics
Agreement enables Biohaven to exercise option on up to three of Artizan’s candidates for the treatment of inflammatory bowel disease Series A-2 led by Hatteras Venture Partners and Biohaven Donnie…
February 18, 2021
FDA approves G1 Therapeutics’ COSELA™ (TRILACICLIB): The first and only myeloprotection therapy to decrease the incidence of chemotherapy-induced myelosuppression
- COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with extensive-stage small cell lung cancer being treated with chemotherapy - - Myeloprotective efficacy of COSELA resulted…
February 18, 2021
Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists
Exclusive license for Asia (ex-Japan), Australia and New Zealand; Parties plan to conduct combination studies with BeiGene's anti-PD-1 antibody tislelizumab BOSTON & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--Feb. 17, 2021-- Boston Immune Technologies and Therapeutics, Inc. (BITT), a privately held developer of…
October 1, 2020
BIAL Goes Global with New US Research Center and Acquisition of Promising Parkinson’s Disease Programs
BIAL Biotech to be based in Cambridge, Massachusetts and will be a ResearchCenter of Excellence dedicated to genetically-defined Parkinson’s disease• LTI-291 clinical program and other research programs in Parkinson's diseaseacquired…
August 21, 2020
Kymera Therapeutics Announces Pricing of Upsized Initial Public Offering
WATERTOWN, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins…
August 19, 2020
Trefoil Therapeutics Begins First Clinical Trial of Regenerative Treatment for Patients with Corneal Endothelial Dystrophies
Phase 1/2 “INTREPID” trial to evaluate safety and ability of engineered FGF-1 to regenerate corneal endothelial cells August 19, 2020 07:00 AM Eastern Daylight Time SAN DIEGO--(BUSINESS WIRE)--Trefoil Therapeutics today…
August 14, 2020
Atsena Therapeutics acquires exclusive rights to Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis
Therapy currently being evaluated in Phase I/II clinical study Company formed with $8.15 million Series 1; led by founding investors Hatteras Venture Partners and the Foundation Fighting Blindness DURHAM, N.C.,…